Subject: To understand the prevalence of genetic mutation, current diagnostic practices & treatment choices in management of breast, prostate & pancreatic cancer in India
Breast cancer the most common cancer among females whereas prostate is 6th most common cancer among males in India. Targeted therapies can be used for the management of BRCA mutation positive breast, prostate, pancreatic cancer.
So far PARP inhibitors were not accessible to all Indian patients due to cost. Considering the fact of it being available in generic space, even diagnostic testing for identification of right patient is increasing. It is crucial to understand prevalence of BRCA mutation in HER2-ve breast cancer, average treatment durations with different PARP inhibitors, treatments choices of doctors for the management of BRCA+ve HER2-ve Breast, Prostate, pancreatic cancer.
We invite you to participate in this survey and share relevant information about the prevalence of genetic mutations, treatment modalities being used in real world practice in India.
We trust you and we are partners in promoting safe effective medical therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})